Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Hotspot mutations of Ras drive cell transformation and tumorigenesis. Less frequent mutations in Ras are poorly characterized for their oncogenic potential. Yet insight into their mechanism of action may point to novel opportunities to target Ras. Here, we show that several cancer-associated mutations in the switch III region moderately increase Ras activity in all isoforms. Mutants are biochemically inconspicuous, while their clustering into nanoscale signaling complexes on the plasma membrane, termed nanocluster, is augmented. Nanoclustering dictates downstream effector recruitment, MAPK-activity, and tumorigenic cell proliferation. Our results describe an unprecedented mechanism of signaling protein activation in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 8×
“The exact molecular and cellular mechanisms that lead to the observed phenotypes are still largely unclear (Prior et al., 2012).”
InfluentialDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 1×
“Ras hyperactivation is a hallmark of cancer and has long been considered to be pharmacologically intractable (Cox et al., 2014).”
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543 · cited 2×
“, it is well understood that hot-spot mutations in codons 12, 13, and 61 (Scheffzek et al., 1997), which account for >99% of Ras mutations (Prior et al.”
Shin, S. I., Freedman, V. H., Risser, R., & Pollack, R. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.11.4435 · Cited by 738 · cited 1×
“In the anchorage-independent colony formation assay, which correlate typically with in vivo tumorigenicity (Shin et al., 1975).”
A molecular timescale of eukaryote evolution and the rise of complex multicellular life
Hedges, S. B., Blair, J. E., Venturi, M. L., & Shoe, J. L. (2004) · BMC Evolutionary Biology · doi:10.1186/1471-2148-4-2 · Cited by 578
Kinetics of interaction of nucleotides with nucleotide-free H-ras p21
John, J., Sohmen, R., Feuerstein, J., Linke, R., Wittinghofer, A., & Goody, R. S. (1990) · Biochemistry · doi:10.1021/bi00477a025 · Cited by 429
Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway
Nan, X., Tamgüney, T. M., Collisson, E. A., Lin, L.-J., Pitt, C., Galeas, J., Lewis, S., Gray, J. W., McCormick, F., & Chu, S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509123112 · Cited by 273 · cited 2×
“Evidence for dimers of H-ras and N-ras in the membrane (Lin et al., 2014; Güldenhaupt et al., 2012) and K-ras even in solution (at micromolar concentrations) has recently been provided (Muratcioglu et al., 2015; Nan et al., 2015).”
Mazhab-Jafari, M. T., Marshall, C. B., Smith, M. J., Gasmi-Seabrook, G. M. C., Stathopulos, P. B., Inagaki, F., Kay, L. E., Neel, B. G., & Ikura, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419895112 · Cited by 220
GTP-Dependent K-Ras Dimerization
Muratcioglu, S., Chavan, T. S., Freed, B. C., Jang, H., Khavrutskii, L., Freed, R. N., Dyba, M. A., Stefanisko, K., Tarasov, S. G., Gursoy, A., et al. (2015) · Structure · doi:10.1016/j.str.2015.04.019 · Cited by 202 · cited 4×
“Evidence for dimers of H-ras and N-ras in the membrane (Lin et al., 2014; Güldenhaupt et al., 2012) and K-ras even in solution (at micromolar concentrations) has recently been provided (Muratcioglu et al., 2015; Nan et al., 2015).”
Influential
Cited by
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
Horak, P., Griffith, M., Danos, A. M., Pitel, B. A., Madhavan, S., Liu, X., Chow, C., Williams, H., Carmody, L., Barrow-Laing, L., et al. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2022.01.001 · Cited by 257
Intrinsically disordered proteins and membranes: a marriage of convenience for cell signalling?
Cornish, J., Chamberlain, S. G., Owen, D., & Mott, H. R. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200467 · Cited by 69
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Nussinov, R., Zhang, M., Maloney, R., Liu, Y., Tsai, C.-J., & Jang, H. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167569 · Cited by 66
Metadata
- Authors
- Šolman, M., Ligabue, A., Blaževitš, O., Jaiswal, A., Zhou, Y., Liang, H., Lectez, B., Kopra, K., Guzmán, C., Härmä, H., Hancock, J. F., Aittokallio, T., & Abankwa, D.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2015-08-14
- Volume
- 4
- Pages
- e08905-e08905
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W2164211455
- Cited by
- 50
- References
- 11
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation. https://app.cochat.ai/papers/10.7554/elife.08905
- The paper
- Šolman, M., Ligabue, A., Blaževitš, O., Jaiswal, A., Zhou, Y., Liang, H., Lectez, B., Kopra, K., Guzmán, C., Härmä, H., Hancock, J. F., Aittokallio, T., & Abankwa, D. (2015). Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation. eLife. https://doi.org/10.7554/elife.08905
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.